Primary Preventive Ventricular Tachycardia Ablation In High-Risk Patients Who Receive A Prophylactic Implantable Cardioverter Defibrillator (PRIMARY PREVENT-VT TRIAL)
This prospective, multicenter, open-label, randomized-controlled trial compares two treatment strategies in high-risk ischemic cardiomyopathy (ICM) patients referred for primary ICD implantation. Participants will be randomized to receive either prophylactic VT ablation within three months of ICD implantation or continued medical management. The primary objective is to assess the efficacy of preventive VT ablation versus medical management in reducing VT arrhythmia burden.
• Age ≥ 18 years (no upper age limit)
• Willing and able to provide informed consent
• Candidate for a primary prevention ICD/CRT-D per ESC guidelines17
• Ischemic cardiomyopathy (ICM) with left ventricular ejection fraction (LVEF) ≤ 35%
• Willing and able to receive an ICD
• Willing and able to undergo catheter-based VT ablation
⁃ One or more of the following:
• MADIT-ICD Benefit Score \>75
• History of nonsustained ventricular tachycardia (NSVT)
• Multiple premature ventricular complexes (PVCs ≥10%)